Survivin (18-27)
Need Assistance?
  • US & Canada:
    +
  • UK: +

Survivin (18-27)

* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

A peptide fragment of Survivin. Survivin, also called BIRC5 , is a member of the apoptosis inhibitor protein family containing a baculovirus domain. Survivin is overexpressed in most human cancers but rarely expressed in normal differentiated adult tissues.

Category
Others
Catalog number
BAT-009831
Synonyms
Survivin (18-27)(modK); Sur18K10; Baculoviral IAP repeat-containing protein 5 (18-27)
Sequence
RISTFKNWPK
Storage
Common storage 2-8°C, long time storage -20°C.
1. Survivin: a dual player in healthy and diseased skin
Katiuscia Dallaglio, Alessandra Marconi, Carlo Pincelli J Invest Dermatol. 2012 Jan;132(1):18-27. doi: 10.1038/jid.2011.279. Epub 2011 Sep 8.
Survivin belongs to the inhibitor of apoptosis (IAP) protein family, and, in addition to the antiapoptotic functions, it also regulates the cell cycle. The survivin gene generates five major isoforms with diverse and opposite functions. Survivin is highly expressed in cancer and in few normal adult tissues, including skin. It is mostly detected in the nucleus of keratinocyte stem cells (KSCs), but it is also expressed in melanocytes and fibroblasts. Survivin isoforms are differentially detected in subpopulations of human keratinocytes, exerting contrasting activities. Survivin has an important role in the regulation of cell cycle in keratinocytes, and it protects these cells from anoikis and UV-induced apoptosis. In melanoma, survivin is abundantly expressed, and its subcellular localization varies depending upon tumor thickness and invasiveness. Survivin overexpression has been shown in squamous cell carcinoma (SCC), and it is also involved in UVB-induced carcinogenesis. The presence of survivin both in the nucleus and in the cytoplasm throughout the epidermal layers of psoriatic lesions suggests the involvement of this protein in the keratinocyte alterations typical of this disease. Additional studies on the expression of survivin isoforms and their subcellular localization in relation to function will confirm the key role of survivin in the skin and will open the field to new therapeutic strategies for many cutaneous conditions.
2. CpG oligodeoxynucleotide-adjuvanted fusion peptide derived from HBcAg epitope and HIV-Tat may elicit favorable immune response in PBMCs from patients with chronic HBV infection in the immunotolerant phase
Suna Wang, Qunying Han, Guoyu Zhang, Ni Zhang, Zhu Li, Jinghong Chen, Yi Lv, Na Li, Fanfan Xing, Ningqiang Tian, Qianqian Zhu, Zhengwen Liu Int Immunopharmacol. 2011 Apr;11(4):406-11. doi: 10.1016/j.intimp.2010.12.005. Epub 2010 Dec 21.
The absence or insufficiency of specific immune response results in chronic hepatitis B virus (HBV) infection and immunotolerance. Therapeutic fusion peptide containing hepatitis B core antigen (HBcAg)(18-27) CTL epitope and human immunodeficiency virus (HIV)-Tat(49-57) peptide was synthesized and the activity when adjuvanted with CpG oligodeoxynucleotide (CpG ODN) was evaluated in PBMCs from patients with chronic HBV infection in the immunotolerant phase in this study. Results showed that the fusion peptide when adjuvanted with CpG ODN could induce significantly higher levels of IFN-γ and IL-4 in the PBMCs compared with fusion peptide or CpG ODN alone. The magnitude of augmentation to IFN-γ by the fusion peptide plus CpG ODN was much higher than that to IL-4. Cytotoxicity assay showed that the percentage of target cell lysis by effector cells stimulated by fusion peptide plus CpG ODN was higher than that in fusion peptide or CpG ODN alone at most of the E/T ratios tested. The magnitude augmented to IFN-γ by fusion peptide plus CpG ODN was also much higher than that to the percentage of target cell lysis. It is concluded that HBcAg(18-27) and HIV-Tat(49-57) fusion peptide when adjuvanted with CpG ODN may have much higher potency to induce IFN-γ than to induce IL-4 and cytotoxicity, suggesting the favorable immune response towards noncytolytic inactivation of the virus mediated by IFN-γ and the potential to break the tolerant state in chronic HBV infection.
3. [Expression of survivin and its significance in esophageal cancer]
Hong-Xia Zhu, Yi-Hua Wang, Cui-Qi Zhou, Guo Zhang, Jin-Feng Bai, Lan-Ping Quan, Zhi-Hua Liu, Ning-Zhi Xu Zhonghua Zhong Liu Za Zhi. 2005 Jan;27(1):22-4.
Objective: To detect the expression of survivin in esophageal cancer and elucidate its function in esophageal cancer. Methods: Expression of surviv in was detected in paired normal and tumor tissues from patients with esophageal cancer by semi-quantitative RT-PCR. A dominant-negative survivin (surT34A) was transfected into esophageal cancer EC9706 cells (EC9706surT34A). Colony formation and apoptosis of the parental and surT34A-transfected EC9706 cells were examined in soft agar and by flow cytometry, respectively. Results: Survivin mRNA expression of tumor tissues was higher than normal tissues in 18/27 (66.7%) samples. The expression level of survivin mRNA in tumor tissues (2.08 +/- 1.32) was significantly higher than that in normal tissues (1.22 +/- 1.09). EC9706 surT34A cells formed fewer colonies on agar than the non-transfected ones. After serum withdrawal, EC9706surT34A had higher apoptotic ratio than control, but survivin could reduce the apoptotic ratio. Conclusion: Overexpression of survivin is a common eventin esophageal cancer. The dominant-negative survivin can partially inhibit the malignant phenotype of esophageal cancer.
Online Inquiry
Verification code
Inquiry Basket